摘要
因循证医学(EMB)证明长期服用非甾体类抗炎药(NSAIDs)可以降低消化道肿瘤发病率,故而NSAIDs的使用备受关注。塞来昔布作为NSAIDs中的高选择性环氧合酶2(COX-2)抑制剂,其较传统NSAIDs具有毒副作用少、安全性高等特点,被广泛应用于抗肿瘤领域的研究。然而塞来昔布在一些不表达COX-2的肿瘤细胞株中亦能发挥有效的抗肿瘤作用。为此,本文就塞来昔布介导的COX-2非依赖的核因子κB(NF-κB)抗肿瘤途径的研究进行综述,通过分析塞来昔布在用于肿瘤细胞实验中介导NF-κB途径引起的多种细胞学效应,更深入、全面地揭示塞来昔布抗肿瘤机制。
Evidence-based studies show that long-term use of non-steroidal anti-inflammatory drugs(NSAIDs)can reduce the incidence of gastrointestinal tumors,so the use of NSAIDs has attracted much attention.Celecoxib,a highly selective cyclooxygenase-2(COX-2)inhibitor in NSAIDs widely used in anti-cancer research,has fewer toxic and side effects and higher safety compared with traditional NSAIDs.Moreover,celecoxib can also be effective in mediating antitumor pathway in some cancer cell lines that do not express COX-2.To this end,this article reviews recent developments in research on celecoxibmediated COX-2-independent NF-κB pathway in tumor therapy,and further and comprehensively reveal the anti-tumor mechanism of celecoxib by analyzing responses of tumor cells during the experiments.
作者
汪煜鹏
赵逵
WANG Yupeng;ZHAO Kui(Department of Gastroenterology,Affiliated Hospital of Zunyi Medical University,Zunyi 563000,China)
出处
《中国全科医学》
CAS
北大核心
2020年第9期1195-1198,共4页
Chinese General Practice
作者简介
通信作者:赵逵,教授,主任医师,硕士生导师,E-mail:kuizhao95868@msn.com。
